| Abstrakt: |
A recent study conducted in Aichi, Japan, examined the efficacy and safety of a new extended-release tablet called Pemafibrate. Pemafibrate is a medication used to treat dyslipidemia, a condition characterized by abnormal levels of lipids in the blood. The study aimed to compare the effectiveness of the extended-release tablet to the immediate-release tablet in lowering triglyceride levels in patients with hypertriglyceridemia. The results showed that both the extended-release and immediate-release tablets were equally effective in reducing triglyceride levels, with the higher dose of the extended-release tablet demonstrating a more potent effect. This research provides valuable insights into the potential benefits of Pemafibrate as a treatment option for patients with high triglyceride levels. [Extracted from the article] |
